16093-16-6

Basic information

• Product Name: 5-(2,3,4-TRIMETHOXYPHENYL)-5-OXOVALERIC ACID
• Synonyms: 5-(2,3,4-TRIMETHOXYPHENYL)-5-OXOVALERIC ACID
• CAS NO: 16093-16-6
• Molecular Formula: C₁₄H₁₈O₆
• Molecular Weight: 282.3
• Mol File: 16093-16-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 470.5°C at 760 mmHg
• Flash Point: 175°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 1.17E-09mmHg at 25°C
• Refractive Index: 1.517
• CAS DataBase Reference: 5-(2,3,4-TRIMETHOXYPHENYL)-5-OXOVALERIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2,3,4-TRIMETHOXYPHENYL)-5-OXOVALERIC ACID(16093-16-6)
• EPA Substance Registry System: 5-(2,3,4-TRIMETHOXYPHENYL)-5-OXOVALERIC ACID(16093-16-6)

Safety Data

• Hazardous Substances Data: 16093-16-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H18O6/c1-18-11-8-7-9(13(19-2)14(11)20-3)10(15)5-4-6-12(16)17/h7-8H,4-6H2,1-3H3,(H,16,17)

Upstream product

• 108-55-4 glutaric anhydride, 
• 634-36-6 1,2,3-trimethoxybenzene 
• 412012-34-1 5-(2,3,4-trimethoxy-phenyl)-5-oxo-pentanoic acid methyl ester 
• 5205-39-0 ethyl glutaroyl chloride 

Downstream Products

• 79623-04-4 5-(3,4-dimethoxy-2-hydoxyphenyl)valeric acid 
• 859785-14-1 5-(2',3',4'-trimethoxyphenyl)pentanoic acid 
• 412012-34-1 5-(2,3,4-trimethoxy-phenyl)-5-oxo-pentanoic acid methyl ester 

Relevant articles and documents

Synthesis of diverse analogues of Oenostacin and their antibacterial activities

Several diverse analogues of Oenostacin, a naturally occurring potent antibacterial phenolic acid derivative, have been synthesized. A small library with more than forty analogues having different aromatic rings and varied side chains has been achieved through solution phase synthesis. Some of these analogues, that is, 22, 23 and 42, possessed potent antibacterial activities against Staphylococcus epidermidis and Staphylococcus aureus having EC50 ranging from 0.49 to 0.67 μM as compared to Oenostacin (EC50 = 0.12 μM).

Combretastatin analogs with tubulin binding activity

Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.